Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

A Phase III Randomized, Double Blind, Placebo-controlled Trial Comparing Capecitabine Plus Sorafenib Versus Capecitabine Plus Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

The objective of this phase-III trial is to compare the efficacy and safety of sorafenib in combination with capecitabine versus capecitabine in combination with placebo in the treatment of subjects with locally advanced or metastatic HER2-negative breast cancer who are resistant to or have failed prior taxane and an anthracycline or for whom further anthracycline therapy is not indicated. After signing consent there can be up to 28 days before starting the treatment during which time a number of tests will be carried out which will include tumor evaluations and medical history. The following tests and evaluations will have to be done within 7 days of the start of treatment,on Day 1 of every cycle and at the end of study: Electrocardiogram, blood tests, patient quality of life questionnaires and a complete physical exam and vital signs. Treatment will be given in 21 day cycles with sorafenib/placebo to be taken every day for 21 days and capecitabine to be taken for the first 14 days. Patients will come in weekly for the first 6 weeks and then on Day1 for every cycle after the first 2 cycles. During the weekly visits the subjects will be check for any side effects and blood draws will happen for the study on Day 1 of each cycle. Subjects will be followed for overall survival.

Study Overview

• Status: Completed
• Conditions: Breast Cancer
• Intervention / Treatment: Drug: Sorafenib (Nexavar, BAY43-9006); Drug: Capecitabine; Drug: Placebo

Detailed Description

Research summary (NRES, UK):

Breast cancer is the most commonly diagnosed cancer in women and the leading cause of cancer-related death among women worldwide.

However, despite advances in treatment of the early-stage disease, about 25-40% of patients will develop recurrence or spread to other parts of the body that is largely incurable. The average survival of patients with breast cancer that has spread to other parts of the body (metastasis) is 2 to 3 years after diagnosis, and although a number of treatment options are available, including various chemotherapy agents, no single standard of care exists.

The study drug (Sorafenib) works by inhibiting certain pathways in the body that contribute to tumour growth and the formation of new blood vessels (angiogenesis). Angiogenesis plays an important role in the development, transformation and spread of breast cancer. Capecitabine is an approved chemotherapy drug for patients whose breast cancer has spread to other parts of the body (metastatic) and is not responsive to other classes of chemotherapy drugs.

Data from a Phase IIb clinical study suggests that there is a role for the combination of Sorafenib and Capecitabine to treat locally advanced or metastatic breast cancer.

Patients in this confirmatory Phase III study will be randomly assigned to receive either:

• Capecitabine + Sorafenib
• Capecitabine + placebo ("dummy medication" with no active drug)

Participants will continue to receive treatments until there is radiographic or clinical progression of disease, side effects which require them to withdraw, pregnancy, protocol non-compliance or withdrawal of consent. Therefore length of participation will vary for individuals. This study is expected to close 31 March 2013.

This is a multicentre study which will take place across Europe, North and South America, Asia, Australia and South Africa. It is anticipated that approximately 519 participants will be recruited worldwide.

• Study Type: Interventional
• Enrollment (Actual): 537
• Phase: Phase 3

Contacts and Locations

Study Locations

• Argentina
  • Buenos Aires
    • Mar del Plata, Buenos Aires, Argentina, B7600CTO
  • Ciudad Auton. De Buenos Aires
    • Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina, C1280AEB
    • Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina, C1425AWC
• Australia
  • Australian Capital Territory
    • Garran, Australian Capital Territory, Australia, 2605
  • New South Wales
    • Liverpool, New South Wales, Australia, 2170
    • Waratah, New South Wales, Australia, 2298
  • South Australia
    • Adelaide, South Australia, Australia, 5000
  • Victoria
    • Bendigo, Victoria, Australia, 3550
    • Frankston, Victoria, Australia
  • Western Australia
    • Perth, Western Australia, Australia, 6000
• Austria
  • Wien, Austria, 1100
  • Oberösterreich
    • Linz, Oberösterreich, Austria, 4010
• Belgium
  • Brugge, Belgium, 8000
  • Bruxelles - Brussel, Belgium, 1000
  • Edegem, Belgium, 2650
  • Hasselt, Belgium, 3500
  • Liège
    • Liege, Liège, Belgium, 4000
• Canada
  • Quebec
    • Montreal, Quebec, Canada, H2L 4M1
    • Montreal, Quebec, Canada, H3G 1A4
• China
  • Beijing, China, 100021
  • Beijing, China, 100071
  • Nanning, China, 530021
  • Shanghai, China, 200030
  • Tianjin, China, 300060
  • Xi'an, China, 710032
  • Liaoning
    • Shenyang, Liaoning, China, 110001
• Czechia
  • Ceske Budejovice, Czechia, 370 01
  • Nova Ves Pod Plesi, Czechia, 262 04
  • Nymburk, Czechia, 288 02
  • Olomouc, Czechia, 775 20
  • Praha 10, Czechia, 10034
  • Praha 2, Czechia, 128 08
  • Praha 5, Czechia, 150 06
  • Praha 5, Czechia, 150 30
• France
  • Clermont Ferrand Cedex 1, France, 63011
  • Lille, France, 59020
  • Nantes, France, 44805
  • Saint Cloud, France, 92210
  • Toulouse, France, 31052
• Germany
  • Berlin, Germany, 13589
  • Bayern
    • Erlangen, Bayern, Germany, 91054
  • Hessen
    • Frankfurt, Hessen, Germany, 60389
    • Offenbach, Hessen, Germany, 63069
  • Nordrhein-Westfalen
    • Köln, Nordrhein-Westfalen, Germany, 51067
    • Köln, Nordrhein-Westfalen, Germany, 50931
  • Rheinland-Pfalz
    • Mainz, Rheinland-Pfalz, Germany, 55131
  • Sachsen
    • Leipzig, Sachsen, Germany, 04103
  • Sachsen-Anhalt
    • Stendal, Sachsen-Anhalt, Germany, 39576
• Greece
  • Athens, Greece, 11528
  • Heraklion, Greece, 711 10
  • Ioannina, Greece, 45500
  • Larissa, Greece, 41100
  • Patras, Greece, 26500
• Hungary
  • Budapest, Hungary, 1032
  • Nyiregyhaza, Hungary, H-4400
  • Pecs, Hungary, 7624
  • Szentes, Hungary, 6600
  • Szolnok, Hungary, H-5004
• Ireland
  • Cork, Ireland
  • Dublin, Ireland, 9
  • Dublin, Ireland, 7
  • Dublin, Ireland, DUBLIN 4
  • Dublin, Ireland, DUBLIN 8
  • Galway, Ireland
• Israel
  • Beer Sheva, Israel, 8410101
  • Haifa, Israel, 3109601
  • Haifa, Israel, 35152
  • Jerusalem, Israel, 9112001
  • Jerusalem, Israel, 9372212
  • Petah Tikva, Israel, 4941492
  • Ramat Gan, Israel, 5266202
• Italy
  • Emilia-Romagna
    • Bologna, Emilia-Romagna, Italy, 40138
    • Forlì-Cesena, Emilia-Romagna, Italy, 47014
    • Modena, Emilia-Romagna, Italy, 41124
    • Ravenna, Emilia-Romagna, Italy, 48121
  • Lazio
    • Roma, Lazio, Italy, 00161
  • Lombardia
    • Cremona, Lombardia, Italy, 26100
    • Milano, Lombardia, Italy, 20089
    • Monza-Brianza, Lombardia, Italy, 20900
  • Marche
    • Ancona, Marche, Italy, 60126
  • Sicilia
    • Palermo, Sicilia, Italy, 90127
  • Toscana
    • Pisa, Toscana, Italy, 56126
• Japan
  • Chiba, Japan, 260-8717
  • Fukuoka, Japan, 811-1395
  • Kagoshima, Japan, 892-0833
  • Osaka, Japan, 540-0006
  • Aichi
    • Nagoya, Aichi, Japan, 464-8681
  • Ehime
    • Matsuyama, Ehime, Japan, 791-0280
  • Osaka
    • Suita, Osaka, Japan, 565-0871
  • Saitama
    • Hidaka, Saitama, Japan, 350-1298
    • Kita-Adachigun, Saitama, Japan, 362-0806
  • Tokyo
    • Bunkyo, Tokyo, Japan, 113-8677
    • Koto-ku, Tokyo, Japan, 135-8550
• Poland
  • Gdansk, Poland, 80-952
  • Gdynia, Poland, 81-519
  • Poznan, Poland, 61-485
• Puerto Rico
  • San Juan, Puerto Rico, 00918
• Russian Federation
  • Chelyabinsk, Russian Federation, 454087
  • Kazan, Russian Federation, 420029
• South Africa
  • Eastern Cape
    • Port Elizabeth, Eastern Cape, South Africa, 6045
  • Gauteng
    • Johannesburg, Gauteng, South Africa, 2196
    • Pretoria, Gauteng, South Africa, 0181
    • Pretoria, Gauteng, South Africa, 0084
    • Pretoria, Gauteng, South Africa, 0081
• Spain
  • A Coruña, Spain, 15006
  • Barcelona, Spain, 08036
  • Barcelona, Spain, 08003
  • Barcelona, Spain, 08035
  • Barcelona, Spain, 08025
  • Lleida, Spain, 25198
  • Madrid, Spain, 28040
  • Madrid, Spain, 28034
  • Madrid, Spain, 28041
  • Madrid, Spain, 28033
  • Madrid, Spain, 28050
  • Palma de Mallorca, Spain, 07198
  • Sevilla, Spain, 41013
  • Sevilla, Spain, 41071
  • Valencia, Spain, 46014
  • Valencia, Spain, 46010
  • Valencia, Spain, 46009
  • A Coruña
    • Santiago de Compostela, A Coruña, Spain, 15706
  • Barcelona
    • Sabadell, Barcelona, Spain, 08208
    • Terrassa, Barcelona, Spain, 08221
  • Castellón
    • Castellón de la Plana, Castellón, Spain, 12002
  • Illes Baleares
    • Palma de Mallorca, Illes Baleares, Spain, 07120
  • Tarragona
    • Reus, Tarragona, Spain, 43204
• Sweden
  • Stockholm, Sweden, 171 76
  • Stockholm, Sweden, 118 83
• United Kingdom
  • London, United Kingdom, NW3 2QG
  • Manchester, United Kingdom, M20 4BX
  • Northwood, United Kingdom, HA6 2RN
  • Cornwall
    • Truro, Cornwall, United Kingdom, TR1 3LJ
  • Nottinghamshire
    • Nottingham, Nottinghamshire, United Kingdom, NG5 1PB
• United States
  • California
    • Greenbrae, California, United States, 94904-2007
    • Sylmar, California, United States, 91342
  • Florida
    • West Palm Beach, Florida, United States, 33407
  • Illinois
    • Joliet, Illinois, United States, 60435
  • Indiana
    • Evansville, Indiana, United States, 47713
  • Kentucky
    • Louisville, Kentucky, United States, 40207
  • Massachusetts
    • Boston, Massachusetts, United States, 02114
    • Boston, Massachusetts, United States, 02115-6084
  • Mississippi
    • Jackson, Mississippi, United States, 39202
  • Missouri
    • Springfield, Missouri, United States, 65804
  • New Mexico
    • Albuquerque, New Mexico, United States, 87131
  • New York
    • Lake Success, New York, United States, 11042
  • North Carolina
    • Durham, North Carolina, United States, 27710
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States, 19104
  • Tennessee
    • Bristol, Tennessee, United States, 37620
    • Memphis, Tennessee, United States, 38120
  • Texas
    • El Paso, Texas, United States, 79905
  • Vermont
    • Burlington, Vermont, United States, 05405
  • Wisconsin
    • Madison, Wisconsin, United States, 53792

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Age is >=18 years
• Subject has histologically or cytologically confirmed HER2-negative adenocarcinoma of the breast. HER2 status should be determined by an accredited laboratory
• Subject has locally advanced or metastatic disease; locally advanced disease must not be amenable to resection with curative intent. Must have measurable or non-measurable disease (according to RECIST [Response Evaluation Criteria for Solid Tumors] 1.1)
• All computer tomography (CT; with contrast) and magnetic resonance imaging (MRI) used to document disease must have been done <= 4 weeks before randomization. Bone scans (if clinically indicated) must have been done <= 12 weeks prior to randomization
• Subject must have received up to two prior chemotherapy regimens (adjuvant/neo-adjuvant treatments are considered one regimen), and no more than one prior regimen for advanced and/or metastatic disease. Chemotherapy regimens include both targeted and biologic therapy
• Prior regimens must have included an anthracycline (eg, doxorubicin, epirubicin) and a taxane (eg, paclitaxel, docetaxel), either in combination or in separate regimens, in either the neo-adjuvant/adjuvant or the metastatic setting or both, as either monotherapy or as part of a combination with another agent. Sequential regimens will count as a single regimen; multiple neo-adjuvant / adjuvant regimens will count as a single regimen
• Subjects are either resistant to or have failed prior taxane and anthracycline OR Resistant to or have failed prior taxane AND for whom further anthracycline therapy is not indicated (for example, intolerance or cumulative doses of doxorubicin or doxorubicin equivalents [for example, epirubicin)
• Subjects who relapse beyond 12 months after the last taxane or anthracycline dose given in the adjuvant, neo-adjuvant, or metastatic setting are eligible. Further therapy with the agent(s) for a subsequent regimen must have been considered and ruled out, for example due to prior toxicity or intolerance, or based on the local standard of practice
• Prior experimental chemotherapy treatment is allowed, provided it is given in combination with at least one drug approved for the treatment of breast cancer (excluding drugs that target VEGF [Vascular Endothelial Growth Factor] or VEGFR [Vascular Endothelial Growth Factor Receptor], eg, bevacizumab, brivanib, sunitinib, vatalinib).
• Prior hormonal therapy for locally advanced or metastatic breast cancer is allowed. Subjects who are refractory to hormonal therapy are allowed.
• Prior neo-adjuvant or adjuvant chemotherapy is allowed.
• Subject must have discontinued prior chemotherapy (including both targeted and biologic therapies), prior therapeutic radiation therapy, or prior hormonal therapy for locally advanced or metastatic disease >= 4 weeks (28 days) before randomization. Start of study treatment is allowed within less than 28 days of the prior therapy provided that 5 half-lives of the prior treatment drug(s) have elapsed
• ECOG (Eastern Cooperative Oncology Group) performance status 0 or 1
• Adequate bone marrow, liver and renal function within 7 days prior to randomization
• All acute toxic effects of any prior treatment have resolved to NCI-CTCAE (National Cancer Institute-Common Terminology Criteria for Adverse Events) v4.0 Grade 1 or less
• Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to randomization
• Subjects (men and women) of childbearing potential must agree to use adequate contraception beginning at the signing of the ICF (Informed Consent Form) until at least 30 days after the last dose of study drug.
• Subject must be able to swallow and retain oral medication

Exclusion Criteria:

• HER2 positive breast cancer
• Unknown hormone receptor status (estrogen and progesterone receptor).
• Subjects with bilateral breast cancer or a history of two distinct breast cancers.
• Subjects with inflammatory breast carcinoma.
• Subjects who have received no prior taxane and anthracycline for the treatment of breast cancer (either in adjuvant, neo-adjuvant or metastatic setting).
• Prior use of sorafenib or capecitabine
• Subjects considered by the treating investigator to be appropriate candidates for hormonal therapy as current treatment for locally advanced/metastatic breast cancer
• Subjects with locally advanced disease who are considered by the treating investigator to be appropriate candidates for radiation therapy as current treatment for locally advanced breast cancer
• Subjects with active brain metastases or leptomeningeal disease.
• Subjects with seizure disorder requiring medication.
• Radiation to any lesions <= 4 weeks prior to randomization. Palliative radiation to bone metastasis for pain control is permitted with provisions
• Major surgery, open biopsy, or significant traumatic injury <= 4 weeks
• Evidence or history of bleeding diathesis or coagulopathy. Uncontrolled hypertension, active or clinically significant cardiac disease. Subject with thrombotic, embolic, venus or arterial events
• Subjects with any hemorrhage/bleeding event of NCI-CTCAE v4.0 Grade 3 or higher within 4 weeks before randomization
• Subjects with an infection of NCI-CTCAE v4.0 > Grade 2
• Subjects with a history of human immunodeficiency virus infection or current chronic or active hepatitis B or C infection.
• Subjects who have used strong CYP3A4 inducers (eg, phenytoin, carbamazepine, phenobarbital, St. John's Wort [Hypericum perforatum], dexamethasone at a dose of greater than 16 mg daily, or rifampin [rifampicin], and/or rifabutin) within 28 days before randomization.
• Subjects with any previously untreated or concurrent cancer that is distinct in primary site or histology from breast cancer
• Subjects with a history DHPD (Dihydropyrimidine dehydrogenase) reaction to fluropyrimidine or history of known or suspected allergy or hypersensitivity to any of the study drugs
• Presence of a non-healing wound, non-healing ulcer, or bone fracture
• Women pregnant or breast feeding
• Any condition which, in the investigator's opinion, makes the subject unsuitable for trial participation

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Sorafenib (Nexavar, BAY43-9006) + Capecitabine; Capecitabine was administered orally at a dose of 1,000 milligram per square meter (mg/m^2) twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle. Sorafenib was administered orally at a dose of 600 mg (200 mg in the morning, 400 mg in the evening) daily, continuously (that is, Days 1 to 21, inclusive). A treatment cycle consisted of 21 days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m^2 twice daily and sorafenib dose to a total daily dose of 800 mg for that subject.	Drug: Sorafenib (Nexavar, BAY43-9006); Capecitabine was administered orally at a dose of 1,000 milligram per square meter (mg/m^2) twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle. Sorafenib was administered orally at a dose of 600 mg (200 mg in the morning, 400 mg in the evening) daily, continuously (that is, Days 1 to 21, inclusive). A treatment cycle consisted of 21 days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m^2 twice daily and sorafenib dose to a total daily dose of 800 mg for that subject.; Drug: Capecitabine; Capecitabine was administered orally at a dose of 1,000 milligram per square meter (mg/m^2) twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle.days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m^2 twice daily,
Placebo Comparator: Placebo + Capecitabine; Capecitabine was administered orally at a dose of 1,000 mg/m^2 twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle. Placebo matching to sorafenib was administered orally, 3 tablets (1 tablet in the morning, 2 tablets in the evening) daily, continuously (that is, Days 1 to 21, inclusive). A treatment cycle consisted of 21 days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m^2 twice daily and placebo dose to a total daily dose of 4 tablets (2 tablets twice daily) for that subject.	Drug: Capecitabine; Capecitabine was administered orally at a dose of 1,000 milligram per square meter (mg/m^2) twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle.days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m^2 twice daily,; Drug: Placebo; Capecitabine was administered orally at a dose of 1,000 mg/m^2 twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle. Placebo matching to sorafenib was administered orally, 3 tablets (1 tablet in the morning, 2 tablets in the evening) daily, continuously (that is, Days 1 to 21, inclusive). A treatment cycle consisted of 21 days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m^2 twice daily and placebo dose to a total daily dose of 4 tablets (2 tablets twice daily) for that subject.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression-free Survival (PFS) Assessed by the Independent Review Panel According to Response Evaluation Criteria for Solid Tumors (RECIST) 1.1	PFS was defined as the time from date of randomization to disease progression, radiological or death due to any cause, whichever occurs first. Per RECIST version 1.1, progressive disease was determined when there was at least 20% increase in the sum of diameters of the target lesions, taking as a reference the smallest sum on study (this included the baseline sum if that was the smallest sum on trial). In addition to a relative increase of 20%, the sum had demonstrated an absolute increase of at least 5 mm. Appearance of new lesions and unequivocal progression of existing non-target lesions was also interpreted as progressive disease. Participants without progression or death at the time of analysis were censored at their last date of evaluable tumor evaluation. Median and other 95% confidence intervals (CIs) computed using Kaplan-Meier estimates.	From randomization of the first participant until approximately 3 years or until disease radiological progression

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Survival (OS)	OS was defined as the time from date of randomization to death due to any cause. Participants still alive at the time of analysis were censored at their last known alive date. Median and other 95% CIs computed using Kaplan-Meier estimates.	From randomization of the first participant until approximately 3 years later
Time to Progression (TTP) by Central Review	TTP was defined as the time from date of randomization to disease radiological progression by central review. Per RECIST version 1.1, progressive disease was determined when there was at least 20% increase in the sum of diameters of the target lesions, taking as a reference the smallest sum on study (this included the baseline sum if that was the smallest sum on trial). In addition to a relative increase of 20%, the sum had demonstrated an absolute increase of at least 5 mm. Appearance of new lesions and unequivocal progression of existing non-target lesions was also interpreted as progressive disease. Participants without progression or death at the time of analysis were censored at their last date of evaluable tumor evaluation. Median and other 95% confidence intervals (CIs) computed using Kaplan-Meier estimates.	From randomization of the first participant until approximately 3 years later or until disease radiological progression
Objective Response Rate (ORR) by Central Review	ORR was defined as the best tumor response (Complete Response [CR] or Partial Response [PR]) observed during treatment or within 30 days after termination of study treatment, assessed according to the RECIST version 1.1. CR=all target lesions disappeared, and any pathological lymph node, whether target or non-target, had a reduction in short axis to <10 mm. If any residual lesion was present, cyto-histology was made available to unequivocally document benignity. PR=at least 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. ORR=CR+PR. CR and PR were confirmed by another scan at least 4 weeks later.	From randomization of the first participant until approximately 3 years later or until disease radiological progression
Disease Control Rate (DCR) by Central Review	DCR was defined as the proportion of participants whose best response was CR, PR, stable disease (SD) or Non-CR/Non-PD. Per RECIST version 1.1, CR=all target lesions disappeared, any pathological lymph node, target/non-target, a reduction in short axis to <10 mm. PR=at least 30% decrease in the sum of diameters of target lesions taking as reference baseline sum diameters. PD=at least 20% increase in the sum of diameters of the target lesions, taking as a reference smallest sum on study. Appearance of new lesions and unequivocal progression of existing non-target lesions. SD=neither sufficient shrinkage qualified for PR nor sufficient increase qualified for PD, taking smallest sum of diameters as a reference. Non-CR/Non-PD=persistence of 1/more non-target lesion(s) and/or maintenance of tumor marker level above normal limits. DCR=CR+PR+SD or Non-CR/Non-PD. CR and PR confirmed by another scan at least 4 weeks later. SD and Non-CR/Non-PD documented at least 6 weeks after randomization.	From randomization of the first participant until approximately 3 years later or until disease radiological progression
Duration of Response (DOR) by Central Reader	DOR was defined as the time from date of first response (CR or PR) to the date when PD is first documented, or to the date of death, whichever occurred first according to RECIST version 1.1. CR=all target lesions disappeared, and any pathological lymph node, whether target or non-target, had a reduction in short axis to <10 mm. If any residual lesion was present, cyto-histology was made available to unequivocally document benignity. PR=at least 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Participants still having CR or PR and have not died at the time of analysis were censored at their last date of tumor evaluation. DOR defined for confirmed responders only (that is, CR or PR). 'NA' indicates that value could not be estimated due to censored data. Median and 95% CIs were computed using Kaplan-Meier estimates.	From randomization of the first participant until approximately 3 years later or until disease radiological progression

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Patient Reported Outcomes: Functional Assessment of Cancer Therapy-Breast Symptom Index (8 Item) (FBSI-8)	The FBSI-8 was an 8-item questionnaire. Participants responded to each item using a 5-point Likert-type scale ranging from 0 (not at all) to 4 (very much). A total scale score was calculated (range from 0 to 32), with higher scores indicating low symptomatology and reflecting a better Health-Related Quality of Life (HRQoL). The results on the analysis of covariance (ANCOVA) of time-adjusted area under curve (AUC) for the FBSI-8 score were reported. The time-adjusted AUC was calculated by dividing the AUC by duration (in days) over the period of interest, and reported as 'scores on a scale'.	Day 1 of Cycles 1, 3, 5, 7, 9, 11, 13, 16, 19, 22, 25, 28, 31, 34, 37, and end of treatment (EOT, 21 days after last dose of study drug)
Patient Reported Outcomes: Euroqol-5 Dimensions (EQ-5D) - Index Score	The EQ-5D was a generic Quality of life (QoL) based instrument validated in cancer populations. EQ-5D questionnaire contained a 5-item descriptive system of health states (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and visual analogue scale (VAS). A single HRQoL score ranging from -0.59 to 1 was generated from standard scoring algorithm developed by the EuroQoL was the EQ-5D index score, higher scores represent better health status. A change of at least 0.10 to 0.12 points was considered clinically meaningful. The results on the ANCOVA of time-adjusted AUC for the EQ-5D - Index Score were reported. The time-adjusted AUC was calculated by dividing the AUC by duration (in days) over the period of interest, and reported as 'scores on a scale'.	Day 1 of Cycles 1, 3, 5, 7, 9, 11, 13, 16, 19, 22, 25, 28, and EOT (21 days after last dose of study drug)
Patient Reported Outcomes: Euroqol-5 Dimensions (EQ-5D) - Visual Analogue Scale (VAS) Score	The EQ-5D was a generic QoL preference based instrument and has been validated in the cancer populations. VAS was generated from 0 (worst imaginable health state) to 100 (best imaginable health state). This VAS score was referred to as the EQ-5D self-reported health status score. The results on ANCOVA of time-adjusted AUC were reported. The time-adjusted AUC was calculated by dividing the AUC by duration (in days) over the period of interest, and reported as 'scores on a scale'.	Day 1 of Cycles 1, 3, 5, 7, 9, 11, 13, 16, 19, 22, 25, 28, and EOT (21 days after last dose of study drug)
Maximum Observed Drug Concentration (Cmax) of Capecitabine and 5-fluorouracil	Maximum observed drug concentration, directly taken from analytical data. Geometric mean and percentage geometric coefficient of variation (%CV) were reported. In the listed categories below, 'N' signifies the number of evaluable participants for the drug administered.	Pre-dose and 0.5, 1, 2, and 4 hours after capecitabine dosing at Cycle 2, Day 14
Area Under Curve From Time Zero to Last Quantifiable Concentration (AUC[0-tlast]) of Capecitabine and 5-fluorouracil	AUC(0-tlast) is defined as AUC from time 0 to the last data point, calculated up by linear trapezoidal rule, down by logarithmic trapezoidal rule. Geometric mean and percentage geometric coefficient of variation (%CV) were reported. In the listed categories below, 'N' signifies the number of evaluable participants for the drug administered.	Pre-dose and 0.5, 1, 2, and 4 hours after capecitabine dosing at Cycle 2, Day 14
Number of Participants With Treatment-emergent Grade 3 and 4 Laboratory Abnormalities	Hematological (anemia, hemoglobin, international normalized ratio [INR], lymphocyte, neutrophil, platelet, white blood cell [WBC]), biochemical (ALT [alanine aminotransferase], AST [aspartate aminotransferase], GGT [gamma-glutamyl-transferase], lipase, hypoalbuminemia, hypocalcemia, hyperglycemia, hyperuricemia) evaluations were done. Common terminology criteria for adverse events (CTCAE) version 4-Grade 3: Severe or medically significant; hospitalization or prolongation of hospitalization and CTCAE version 4-Grade 4: life-threatening consequences; urgent intervention were indicated.	From the start of study treatment up to 30 days after the last dose

Collaborators and Investigators

• Sponsor: Bayer
• Collaborators: Onyx Therapeutics, Inc.

Publications and helpful links

General Publications

• Baselga J, Costa F, Gomez H, Hudis CA, Rapoport B, Roche H, Schwartzberg LS, Petrenciuc O, Shan M, Gradishar WJ. A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial. Trials. 2013 Jul 22;14:228. doi: 10.1186/1745-6215-14-228.
• Baselga J, Zamagni C, Gomez P, Bermejo B, Nagai SE, Melichar B, Chan A, Mangel L, Bergh J, Costa F, Gomez HL, Gradishar WJ, Hudis CA, Rapoport BL, Roche H, Maeda P, Huang L, Meinhardt G, Zhang J, Schwartzberg LS. RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer. Clin Breast Cancer. 2017 Dec;17(8):585-594.e4. doi: 10.1016/j.clbc.2017.05.006. Epub 2017 May 22.

Helpful Links

• Click here to find information about studies related to Bayer Healthcare products conducted in Europe

Study record dates

Study Major Dates

• Study Start (Actual): February 21, 2011
• Primary Completion (Actual): May 12, 2014
• Study Completion (Actual): October 20, 2017

Study Registration Dates

• First Submitted: October 4, 2010
• First Submitted That Met QC Criteria: November 3, 2010
• First Posted (Estimate): November 4, 2010

Study Record Updates

• Last Update Posted (Actual): November 6, 2018
• Last Update Submitted That Met QC Criteria: October 8, 2018
• Last Verified: October 1, 2018

More Information

Terms related to this study

• Keywords: Breast Cancer; HER2-neu
• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Breast Neoplasms; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antimetabolites, Antineoplastic; Antimetabolites; Antineoplastic Agents; Protein Kinase Inhibitors; Sorafenib; Capecitabine
• Other Study ID Numbers: 12444; 2010-018501-10 (EudraCT Number)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No